The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
SternbergC.N., YagodaA., ScherH.I.Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.J Urol.1985; 133(3): 403–7.
2.
SternbergC.N., YagodaA., ScherH.I.M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.J Urol.1988; 139(3): 461–9.
3.
GabriloveJ.L., JakubowskiA., ScherH.Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.N Engl J Med.1988; 318(22): 1414–22.
4.
ConnorJ.P., OlssonC.A., BensonM.C.Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern.Urology.1989; 34(6): 353–6.
5.
TannockI., GospodarowiczM., ConnollyJ.M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience.J Urol.1989; 142(2 pt 1): 289–92.
6.
SternbergC.N., YagodaA., ScherH.I.Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.Cancer.1989; 64(12): 2448–58.
7.
IgawaM., OhkuchiT., UekiT.Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer.J Urol.1990; 144(3): 662–5.
8.
ScherH., HerrH., SternbergC.M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.Prog Clin Biol Res.1990; 353: 179–86.
9.
LogothetisC.J., DexeusF.H., FinnL.A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.J Clin Oncol.1990; 8(6): 1050–5.
10.
Boutan-LarozeA., MahjoubiM., DrozJ.P.M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.Eur J Cancer.1991; 27(12): 1690–4.
11.
GellerN.L., SternbergC.N., PenenbergD.Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy.Cancer.1991; 67(6): 1525–31.
12.
HeimbachD., WirthM., FrohmullerH.M-VAC versus CisCA—chemotherapy in the treatment of advanced bladder cancer.Urol Int.1992; 48(2): 157–63.
13.
StöckleM., MeyenburgW., WellekS.Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.J Urol.1992; 148(2 pt 1): 302–6.
14.
ScherH.I., GellerN.L., CurleyT.Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.J Clin Oncol.1993; 11(3): 400–7.
15.
MooreM.J., IscoeN., TannockI.F.A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony-stimulating factors in patients with advanced transitional cell carcinoma.J Urol.1993; 150(4): 1131–4.
16.
LoehrerPJSr, ElsonP., DreicerR.Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial.J Clin Oncol.1994; 12(3): 483–8.
17.
SaxmanS.B., PropertK.J., EinhornL.H.Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study.J Clin Oncol.1997; 15(7): 2564–9.
18.
WitjesJ.A., WullinkM., OosterhofG.O.Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma.Eur Urol.1997; 31(4): 414–9.
19.
von der MaaseH., HansenS.W., RobertsJ.T.Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study.J Clin Oncol.2000; 18(17): 3068–77.
20.
SrougiM., SimonS.D.Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: A 5-year followup.J Urol.1994; 151(3): 593–7.
21.
MillikanR., DinneyC., SwansonD.Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.J Clin Oncol.2001; 19(20): 4005–13.
22.
GrossmanH.B., NataleR.B., TangenC.M.Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.N Engl J Med.2003; 349(9): 859–66.
23.
StöckleM., MeyenburgW., WellekS.Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: Long-term results of a controlled prospective study and further clinical experience.J Urol.1995; 153(1): 47–52.
24.
ZinckeH., SenS.E., HahnR.G.Neoadjuvant chemotherapy for locally advanced transitional cell carcinoma of the bladder: Do local findings suggest a potential for salvage of the bladder?Mayo Clin Proc.1988; 63(1): 16–22.
25.
ScherH.I., YagodaA., HerrH.W.Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.J Urol.1988; 139(3): 470–4.
26.
ScherH.I., YagodaA., HerrH.W.Neoadjuvant —VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors.J Urol.1988; 139(3): 475–7.
27.
ScherH., HerrH., SternbergC.Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen.Br J Urol.1989; 64(3): 250–6.
28.
KeatingJ.P., ZinckeH., HahnR.G.Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.Prog Clin Biol Res.1990; 353: 119–27.
29.
GalanteE., FerroniC., BianchiS.Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: Preliminary report of a non-randomized study.J Exp Ther Oncol.1996; 1(4): 237–41.
HerrH.W., BajorinD.F., ScherH.I.Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome.J Clin Oncol.1998; 16(4): 1298–301.
32.
DreicerR., MessingE.M., LoehrerP.J.Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: An Eastern Cooperative Oncology Group pilot study.J Urol.1990; 144(5): 1123–6.
33.
HallM.C., SwansonD.A., DinneyC.P.Complications of radical cystectomy: Impact of the timing of perioperative chemotherapy.Urology.1996; 47(6): 826–30.
34.
LogothetisC., SwansonD., AmatoR.Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma.J Urol.1996; 155(4): 1241–5.
35.
LongH.J., RaysonS., PodratzK.C.Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.Am J Clin Oncol.2002; 25(6): 547–51.
36.
DowdyS.C., BoardmanC.H., WilsonT.O.Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.Am J Obstet Gynecol.2002; 186(6): 1167–73.
37.
PapadimitriouC.A., DimopoulosM.A., GiannakoulisN.A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix.Cancer.1997; 79(12): 2391–5.
38.
LongH.J., CrossW.G., WieandH.S.Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.Gynecol Oncol.1995; 57(2): 235–9.
39.
WilsonT.O., HartmannL.C., LongH.J.Neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) chemotherapy for locally advanced or metastatic cervical and vaginal cancer.Adjuvant Ther Cancer.1993; 7: 366–71.
40.
LongH.J., LangdonR.M., ChaS.S.Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.Gynecol Oncol.1995; 58(2): 240–3.
41.
OkunoS.H., MailliardJ.A., SumanV.J.Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.Cancer.2002; 94(8): 2224–31.
42.
RothB.J.Chemotherapy for advanced bladder cancer.Semin Oncol.1996; 23(5): 633–44.
43.
de Wit R; European Organization for Research and Treatment.Overview of bladder cancer trials in the European Organization for Research and Treatment.Cancer.2003; 97(8 suppl):2120–6.
44.
National Comprehensive Cancer Network. NCCN clinical practice guidelines: Bladder cancer. Available at http://www.nccn.org. Accessed June 25, 2004.
45.
LoehrerPJSr, EinhornL.H., ElsonP.J.A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study.J Clin Oncol.1992; 10(7): 1066–73.
46.
LogothetisC.J., FinnL.D., SmithT.Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.J Clin Oncol.1995; (9):2272–7.
47.
LogothetisC.J., DexeusF.H., SellaA.Escalated therapy for refractory urothelial tumors: Methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor.J Natl Cancer Inst.1990; 82(8): 667–72.
48.
SternbergC.N., de MulderP.H., van OosteromA.T.Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors.Ann Oncol.1993; 4(5): 403–7.
49.
SternbergC.N., de MulderP.H., SchornagelJ.H.European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.J Clin Oncol.2001; 19(10): 2638–46.
50.
SeidmanA.D., ScherH.I., GabriloveJ.L.Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.J Clin Oncol.1993; 11(3): 408–14.
51.
BamiasA, AravantinosG, DeliveliotisC, , and the Hellenic Cooperative Oncology Group. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.J Clin Oncol.2004; 22(2): 220–8.
52.
SimonS.D., SrougiM.Neoadjuvant M-VAC chemotherapy and partial cystectomy for treatment of locally invasive transitional cell carcinoma of the bladder.Prog Clin Biol Res.1990; 353: 169–74.
53.
FarahR., ChodakG.W., VogelzangN.J.Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report).Int J Radiat Oncol Biol Phys.1991; 20(3): 413–7.
54.
VogelzangN.J., MoormeierJ.A., AwanA.M.Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: The University of Chicago experience.J Urol.1993; 149(4): 753–7.
55.
MorrellL.E., LeeY.J., HurleyJ.A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma.Cancer.1998; 82(3): 503–11.
56.
MadajewiczS., MateiD., HentschelP.Actual 5-year survival of patients with stage IIIB breast carcinoma: Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid.Cancer Invest.1999; 17(7): 463–7.
57.
Abdel-WahabM., WolfsonA., RaubW.The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: A phase II trial of neoadjuvant MVAC, surgery, and radiation.Int J Radiat Oncol Biol Phys.1998; 40(4): 875–80.
58.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol.1997; 15(1): 103–9.
59.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery.Am J Health Syst Pharm.1999; 56: 729–64.
60.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Available at http://www.nccn.org. Accessed June 8, 2004.
61.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines.J Clin Oncol.1999; 17(9): 2971–94.
62.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol Oncol.1993; 50: 147–58.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines.J Clin Oncol.2000; 18(20): 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors.Eur J Cancer.1998; 34(12): 1857–64.
68.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors.Curr Opin Hematol.1999; 6(3): 145–51.
69.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care.Eur J Cancer.2000; 36(suppl 1): S15–S21.
70.
LarsonD.L.Treatment of tissue extravasation by antitumor agents.Cancer.1982; 49(9): 1796–9.
71.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
72.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury.Hosp Pharm.2000; 35(1): 57–74.
73.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents.Gastroenterol Clin North Am.1995; 24(4): 969–89.
74.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001, 483–93.
